Daniel Balmaceda, MD
Pulmonary Disease · Overland Park, KSNPI 1104919588
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $832 and has fallen 94.8% since, to $43 in 2025.
Across 159 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$631
- GSK$387
- Boehringer Ingelheim$379
- Grifols USA, LLC$257
- Sanofi$244
- Regeneron Healthcare Solutions, Inc.$231
- plus $885 from 22 others
What the payments were for
- Food & beverage$2,95998%
- Education$542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $631 |
| GSK | 24 | $387 |
| Boehringer Ingelheim | 19 | $379 |
| Grifols USA, LLC | 13 | $257 |
| Sanofi | 10 | $244 |
| Regeneron Healthcare Solutions, Inc. | 9 | $231 |
| Amgen | 9 | $183 |
| Mylan Specialty L.p. | 5 | $96 |
| Genentech USA, Inc. | 4 | $74 |
| Insmed, Inc. | 4 | $65 |
| Advanced Respiratory, Inc | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 5 | $48 |
| Pulmonx Corporation | 2 | $45 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Merck | 2 | $34 |
| Novartis | 2 | $30 |
| Inogen, Inc. | 1 | $23 |
| Harmony Biosciences LLC | 1 | $23 |
| Vapotherm Inc | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Electromed, Inc. | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| United Therapeutics Corporation | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$3,013 in reported general payments places this provider in the 55th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $147,303 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 111 | $90,186 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $81,489 |
| XolairOmalizumab | 18 | $68,581 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $24,225 |
| Spiriva RespimatTiotropium Bromide | 36 | $22,525 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $17,815 |
| SymbicortBudesonide/Formoterol Fumarate | 61 | $16,441 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $12,635 |
| Spiriva HandihalerTiotropium Bromide | 19 | $10,966 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $7,919 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,607 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 20 | $5,387 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 190 | $4,465 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $379 | $189,07081 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $387 | $128,917205 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $631 | $106,628172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Overland Park
- Brietta ForbesOverland Park$10K
- Mitchell TenerOverland Park$6K
- Jason FieserOverland Park$6K
- James KaplanOverland Park$4K
- Trenton NauserOverland Park$1K
- John NelsonOverland Park$1K
- Christine CookOverland Park$1K
- Scott EveloffOverland Park$903
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.